Quest Partners LLC Grows Holdings in Zymeworks Inc. (NYSE:ZYME)

Quest Partners LLC grew its holdings in shares of Zymeworks Inc. (NYSE:ZYME) by 8,049.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 9,209 shares of the company’s stock after purchasing an additional 9,096 shares during the period. Quest Partners LLC’s holdings in Zymeworks were worth $78,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Caprock Group LLC purchased a new position in shares of Zymeworks in the 2nd quarter worth about $129,000. Arizona State Retirement System increased its stake in Zymeworks by 11.1% during the 2nd quarter. Arizona State Retirement System now owns 12,841 shares of the company’s stock valued at $109,000 after purchasing an additional 1,285 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Zymeworks by 23.5% in the second quarter. Victory Capital Management Inc. now owns 58,300 shares of the company’s stock worth $496,000 after buying an additional 11,100 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Zymeworks by 9.0% in the second quarter. Rhumbline Advisers now owns 86,912 shares of the company’s stock worth $740,000 after buying an additional 7,210 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Zymeworks by 1.2% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,930,887 shares of the company’s stock valued at $16,431,000 after buying an additional 23,173 shares during the last quarter. 92.89% of the stock is owned by institutional investors.

Zymeworks Trading Down 1.7 %

NYSE ZYME opened at $12.30 on Wednesday. Zymeworks Inc. has a 12 month low of $6.01 and a 12 month high of $13.14. The stock has a market cap of $873.92 million, a price-to-earnings ratio of -6.87 and a beta of 1.19. The company’s 50 day moving average is $10.78 and its two-hundred day moving average is $9.86.

Zymeworks (NYSE:ZYME) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. Zymeworks had a negative return on equity of 21.97% and a negative net margin of 179.42%. The business had revenue of $19.24 million for the quarter, compared to analysts’ expectations of $23.16 million. During the same period last year, the firm earned ($0.76) earnings per share. Sell-side analysts forecast that Zymeworks Inc. will post -0.85 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Stifel Nicolaus lifted their price objective on Zymeworks from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. HC Wainwright reaffirmed a “neutral” rating and set a $10.00 price target on shares of Zymeworks in a report on Thursday, June 6th.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.